Cancelled due to Coronavirus outbreak: Second Zurich Precision-Oncology Symposium
Precision oncology reveals new opportunities for patients with malignant diseases. This is based on the rapid developments of diagnostic tools, which allow to identifying oncogenic alterations in common as well as in rare malignancies and may provide patients access to targeted treatment options.
The Comprehensive Cancer Center Zürich offers a wide range of platforms for molecular analysis of tumors and liquid biopsies and has established a molecular tumor board, which meets weekly to interpret molecular results and make recommendations for therapy.
At our Second Zürich Precision-Oncology Symposium, a panel of national and international experts will provide an overview and discuss recent developments of the field.